{"id":13749,"date":"2025-03-05T12:16:13","date_gmt":"2025-03-05T12:16:13","guid":{"rendered":"https:\/\/af-net.eu\/?page_id=13749"},"modified":"2026-06-05T08:41:49","modified_gmt":"2026-06-05T08:41:49","slug":"partnerstudie-closure-af-dzhk16","status":"publish","type":"page","link":"https:\/\/www.af-net.eu\/en\/partnerstudie-closure-af-dzhk16\/","title":{"rendered":"Partnerstudie – CLOSURE-AF-DZHK16"},"content":{"rendered":"\n
\n
\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n

CLOSURE-AF-DZHK16<\/strong><\/h2>\n\n\n\n
<\/div>\n\n\n\n

Left atrial appendage CLOSURE in patients with Atrial Fibrillation at high risk of stroke and bleeding compared to medical therapy: a prospective randomized clinical trial<\/p>\n<\/div>\n<\/div>\n<\/div><\/div>\n\n\n\n

<\/div>\n\n\n\n

Ingo EiteL: Interventional stroke prevention in AF<\/em><\/strong><\/strong><\/strong><\/h2>\n\n\n\n
<\/div>\n\n\n\n
<\/div>\n\n\n\n
\n
<\/div>
<\/div>

You are currently viewing a placeholder content from YouTube<\/strong>. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.<\/p> More Information<\/a> <\/div>

Unblock content<\/a> Accept required service and unblock content<\/a> <\/div> <\/div> <\/div><\/div>\n<\/div><\/figure>\n\n\n\n
<\/div>\n\n\n\n
\n
\n
\n

STUDY DESIGN<\/strong><\/strong><\/h2>\n\n\n\n
<\/div>\n\n\n\n

Prospective, multi-centre, national, unblinded, randomized study.<\/p>\n<\/div>\n\n\n\n

\n
\"\"<\/figure>\n<\/div><\/div>\n<\/div>\n\n\n\n
\n
\n
Study objective<\/strong><\/strong><\/h5>\n\n\n\n

Study goal is to determine the clinical benefit of a strategy of percutaneous catheter\u2010based left atrial appendage (LAA) closure in patients with non-valvular atrial fibrillation (NVAF) at high risk of stroke (CHA2DS2\u2010VASc Score \u22652) and bleeding as compared to best medical care.<\/p>\n<\/div>\n\n\n\n

\n
Description<\/strong><\/strong><\/h5>\n\n\n\n

Atrial fibrillation is the most common cardiac arrhythmia in Germany. With atrial fibrillation, there is a risk of clots forming in the heart, particularly in the left atrial appendage), a part of the heart. If these clots come loose, there is a risk of stroke. To prevent strokes, patients with atrial fibrillation can be given medication known as anticoagulants. These drugs prevent the formation of clots in the heart.<\/p>\n<\/div>\n\n\n\n

\n
<\/div>\n\n\n\n

Another treatment option is to close the left atrial appendage with a closure system (occluder), which prevents clots from reaching the brain or the body. After the left atrial appendage has been closed, the blood only needs to be diluted for a short time until the occluder has healed. The CLOSURE-AF study compares the two clinically established treatment approaches (blood thinning with medication and closure of the left heart ear using a catheter technique). Only approved anticoagulants and closure systems will be used.<\/p>\n<\/div>\n<\/div>\n<\/div><\/div>\n\n\n\n

<\/div>\n\n\n\n
\n
\n
\n

Publications<\/strong><\/strong><\/h2>\n\n\n\n
<\/div>\n<\/div>\n<\/div>\n\n\n\n

Landmesser U, Skurk C, Kirchhof P, Lewalter T, Hartung J, Rroku A, Pieske B, Brachmann J, Akin I, Jacobshagen C, Meder B, Zeiher A, Anker SD, Thiele H, Blankenberg S, Massberg S, Schunkert H, Frey N, Joost A, Bergmann M, von Bardeleben RS, Friede T, Placzek M, Suling A, Haeusler KG, Endres M, Wegscheider K, Boldt LH, Eitel I for the CLOSURE-AF Trial Investigators. Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation. N Engl J Med.<\/strong> 2026 Mar 18. doi: 10.1056\/nejmoa2513310.<\/a> Online ahead of print. PMID: 41849741.<\/p>\n\n\n\n